In chronic heart failure, down-regulation of ␤-adrenergic receptor (␤-AR) occurs in cardiomyocytes, resulting in low catecholamine response and impaired cardiac function. To correct the irregularity in the ␤-AR system, ␤-AR gene was transduced in vivo into failing cardiomyocytes. The EpsteinBarr virus (EBV)-based plasmid vector carrying human ␤ 2 -AR gene was injected into the left ventricular muscle of Bio14.6 cardiomyopathic hamsters whose ␤-AR is downregulated in the cardiomyocytes. The echocardiographic examinations revealed that stroke volume (SV) and cardiac output (CO) were significantly elevated at 2 to 4 days after
Introduction
In chronic cardiac failure, persistent excitation of the sympathetic nervous system ultimately leads to downregulation of the ␤-AR in cardiac cells, contributing to the decrease in cardiac function. If a large number of ␤-AR can be expressed in cardiomyocytes through genetic transduction technique, reactivity to catecholamines may be improved, enabling the possible recovery of cardiac contractility. [1] [2] [3] Milano et al 4 established a transgenic mouse constitutively expressing ␤ 2 -AR in the heart. They found a significant increase in the heart rate (HR), as well as improvement in the dp/dt max, an index of isochronic contractility. More recently, Kawahira et al 5 and Kypson et al 6 transduced the ␤ 2 -AR gene ex vivo into donor hearts isolated from pressure-overloaded and normal rats, respectively. They found elevated LV dp/dt max in the heart graft heterotopically transplanted into recipient animals. Maurice et al 7 transduced a normal rabbit heart in vivo with the ␤ 2 -AR gene resulting in the elevation of LV dp/dt max. Although these earlier reports strongly suggest the feasibility of the ␤ 2 -AR gene transfer in terms of gene therapy for heart failure, there have been no reports showing in vivo transduction of the ␤ 2 -AR gene into failing hearts, with attendant cardiac functional restoration.
the ␤ 2 -AR gene transfer. Systemic loading of isoproterenol increased the cardiac parameters more significantly on day 2 to day 7, indicating that the adrenergic response was augmented by the genetic transduction. The same procedure did not affect the cardiac function of normal hamsters. Immunohistochemical examinations demonstrated human ␤ 2 -AR expression in failing cardiomyocytes transduced with the gene. RT-PCR analysis detected mRNA for the transgene in the heart but not in the liver, spleen, or kidney. The procedures may provide a feasible strategy for gene therapy of severe heart failure. Gene Therapy (2000) 7, 2087-2093.
To express a large number of ␤ 2 -AR in failing cardiac muscle cells, it is necessary to find ways to conduct genetic transduction as efficiently as possible. Previously, we reported that a high rate of gene transduction could be achieved in cardiomyocytes in vivo through injection of the Epstein-Barr virus (EBV)-based plasmid. 8 In the present study, we used this method to transduce the ␤ 2 -AR gene into the hearts of cardiomyopathic hamsters. Because direct injection of naked plasmid DNA allows transgene expression specifically in cardiac muscle, and employment of the EBV-based plasmids enables highly efficient gene transduction, our system is considered to be highly appropriate for gene therapy of heart failure.
Results
We first estimated the transduction efficiency in vivo into cardiac muscle using our system. pSES.␤ (Figure 1 ) was inoculated into the hearts of the F1b hamsters, and X-gal staining was performed. The ␤-gal expression was demonstrated in cardiac muscle within approximately 0.1 cm from each injection site (Figure 2a ). This is compatible with our previous finding using normal rat heart. 8 Next, the Bio14.6 hamsters were injected with pSES.␤ 2 -AR or pSES.␤ into the left ventricles, and their cardiac function was evaluated before and 2 and 4 days after the transduction. Figure 3 and Table 1 summarize the cardiac function parameters obtained by the echocardiographic analyses. The hamsters transduced with pSES.␤ 2 -AR gene showed 1.6-fold higher cardiac output (CO) than the pSES.␤-transduced animals on day 4 after the gene transfer (45.6 ± 21.0 ml versus 70.8 ± 21.3 ml, P Ͻ 0.05) (Figure 3 , left lower panel). Cardiac response to isoproterenol, a ␤-AR agonist, was also studied by systemic loading of the drug. On day 4, pSES.␤ 2 -AR-transduced group showed 1.5-, 1.3-and 1.5-fold higher value for fractional shortening (FS), stroke volume (SV) and CO, respectively, in comparison with the pSES.␤-transduced group (FS: 22.7 ± 1.5 ml versus 14.9 ± 5.7 ml, P Ͻ 0.05; SV: 0.256 ± 0.048 ml versus 0.204 ± 0.081 ml, P Ͻ 0.05; CO: 95.8 ± 20.7 ml versus 63.5 ± 31.8 ml, P Ͻ 0.05) (Figure 3 , right panels). In the group given pSES.␤ 2 -AR, the FS was 1.3-fold higher than that obtained before transduction.
(FS: 22.7 ± 1.5 ml versus 17.0 ± 2.9 ml, P Ͻ 0.05) (Figure 3 , right upper panel). The SV and CO of the gene-transduced animals were elevated 1.7-and 1.8-fold on day 2, respectively, in comparison with the levels before the genetic transduction (SV: 0.296 ± 0.023 ml versus 0.170 ± 0.037 ml, P Ͻ 0.005; CO: 112.3 ± 16.7 ml versus 62.9 ± 13.3 ml, P Ͻ 0.005) (Figure 3 , right middle and lower panels). The results indicate that intramyocardial injection of pSES.␤ 2 -AR elicits improvement in cardiac function, as well as augmentation of adrenergic response in the cardiomyopathic hamsters.
To examine the influence of gene transduction on cardiac function of normal animals, the F1b hamsters were also tested. Compared with Bio14.6, the F1b hamsters show smaller SV and CO, due to smaller left ventricular internal dimension at end-diastole (Dd) and left ventricular internal dimension at end-systole (Ds) ( Tables 1 and  2 ). When the F1b were transduced with pSES.␤ 2 -AR or pSES.␤, no significant change was observed in the parameters before and subsequent to genetic transduction, regardless of the plasmid injected (Table 2) . Systemic administration with isoproterenol showed that the adrenergic response in pSES.␤ 2 -AR-transduced F1b was comparable to that in F1b given transduction with control plasmid.
Next, the parameters for cardiac function were computed for the Bio14.6 animals that received pSES.␤ 2 -AR or pSES.␤ transduction, and kinetic changes were monitored up to the 9th day following transduction. In the group transduced with pSES.␤ 2 -AR, significant elevation in the SV and CO was seen on day 2 to 7, compared with the levels before genetic transduction ( Figure 4 ).
The human ␤ 2 -AR was demonstrated in cardiomyocytes from the pSES.␤ 2 -AR-transduced Bio14.6 by immunohistochemical staining (Figure 2b ). In contrast, the hearts of pSES.␤-transduced Bio14.6 did not stain with the anti-human ␤ 2 -AR antibody that does not recognize hamster ␤ 2 -AR (Figure 2c) . RT-PCR experiments demonstrated the transgene-specific mRNA in pSES.␤ 2 -AR-injected heart, but not in liver, kidney or spleen of the same animal ( Figure 5 ). The sense and antisense PCR primers were set corresponding to SR␣ and ␤ 2 -AR sequences, respectively, so that endogenous ␤ 2 -AR mRNA is not amplified. The results indicate that the transgene expression was achieved exclusively in the heart by intra-myocardial injection of the naked EBV-based plasmid vector.
Discussion
In the present study, we succeeded in augmenting cardiac function in cardiomyopathic hamsters by transfecting ␤ 2 -AR gene into the cardiac muscle, in an effort to correct irregularities in the ␤-AR system of failing cardiomyocytes. Administration with isoproterenol resulted in an even more significant improvement in cardiac function. The increase in CO may be ascribed to an increase in the SV rather than that in the HR. As far as we know, Gene Therapy there have been no reports showing in vivo genetic transduction into failing cardiomyocytes.
Unlike the ␤ 2 -AR transgenic mouse, the ␤ 1 -AR transgenic mouse did not show elevated cardiac contractility. 9, 10 Therefore, the ␤ 2 -AR gene may be more suitable for gene therapy of heart failure than the ␤ 1 -AR gene.
The in vivo genetic transduction into heart tissue has been done using many different methods, including direct intra-myocardial injection of naked plasmid DNA 11 and adenoviral vector, 12 and intra-coronary infusion of adenoviral, 13 HVJ-liposome 14 and AAV 15 vectors. We chose the direct intra-muscular injection method so that the gene expression is limited exclusively to cardiac muscle. Actually, we did not detect any evidence for transgene expression in organs other than the heart by RT-PCR ( Figure 5 ). Another advantage of this method is simplicity and safety. Unlike healthy animals, the physiological data of emaciated animals like cardiomyopathic hamsters fluctuate considerably with even a small degree of invasion, and for this reason, it is necessary to minimize the amount of invasion as much as possible. Provided that direct injection is carried out under echocardiography guidance, in vivo naked plasmid injection can be done percutaneously without thoracotomy, so that the degree of invasion with this method is very low. On the other hand, direct injection to cardiac muscle is advantageous over the intra-coronary approach in that the former is also considered appropriate for genetic transduction to cells in an ischemic lesion barely supplied with blood flow. When cardiac incompetence caused by ischemia is considered as a target disease for gene therapy, this point may become important.
An impediment to naked plasmid injection is that the intensity of gene expression is comparatively low. To overcome this problem, we used the EBV-based plasmid vector, which carries oriP and EBNA1 gene from EBV genome. The EBNA1-oriP system facilitates nuclear localization of the plasmid, anchorage of plasmid to nuclear matrix, and transcriptional up-regulation. Previously, we have reported the effectiveness of the vectors in transfecting various cells of human origin both in vitro and in vivo. 8, [16] [17] [18] [19] [20] We also reported that by using the EBV-based plasmid vectors, in vitro transient expression over 10 times higher than that by using conventional plasmids was observed, not only in primate cells but in various types of rodent cells as well. 8 Furthermore, by directly injecting the EBV-plasmid into rat heart, higher rates of genetic transduction and expression were obtained than by injecting conventional plasmids. 8 With naked plasmid injection, genetic transduction is only possible in a limited portion of the heart. We cautiously injected a small amount of a DNA solution into five locations of the heart, ie the front, rear, and side walls of the left ventricle, the septum, and the apex of the heart, to achieve gene expression over a comparatively wide range of cardiac muscle (Figure 2a) . On the other hand, cardiomyocytes are connected by the gap junctions, so that adjacent cells are biochemically aligned and function cooperatively. It has been reported that cAMP, the second messenger mediating adrenergic stimulation, can be transmitted through gap junctions. [21] [22] [23] Taking advantage of this cell-to-cell communication, it may be possible to increase the contractility of cardiac cells which fail to be transduced, but which are connected to neighboring cells that are successfully transduced with the ␤ 2 -AR gene.
In our experiments, no significant change was observed in cardiac function of normal hamsters, while Kypson et al 6 and Maurice et al 7 reported significant elevation in LV-dp/dt max in normal animals given adenovirus vector-mediated transduction of ␤ 2 -AR gene. Because our method involved plasmid injection to cardiac muscle, the intensity of ␤-AR expression may be lower than that in their experiments. Alternatively, the discrepancy may be ascribed to the different parameters measured as an index of cardiac function. We analyzed cardiac function of animals less invasively and more physiologically using echocardiography, 24 while both Kypson et al, 6 Maurice et al 7 and Kawahira et al 5 measured LV-dp/dt max by means of cardiac catheterization.
A variety of therapeutic approaches have been devised to augment the ␤-adrenergic signaling to compensate cardiac function in heart failure (eg administration with dobutamine, 25 prenalterol, 26 xamoterol, 27 and milrinone 28 ). These therapeutic strategies actually improve clinical symptoms during short periods following administration, but fail to significantly prolong the Gene Therapy survival of patients. This may be ascribed to ␤-AR downregulation in failing cardiomyocytes. Therefore, ␤-AR gene transfer may be advantageous over pharmacologic interventions. In contrast, ␤-AR blockade was revealed to be potentially useful for long-term treatment. 29, 30 The concepts are compatible with the manifestations of the transgenic animals overexpressing the myocardial Gs␣, a component of ␤-AR signaling pathway. 31 In cases of chronic severe heart failure beyond conventional medical treatment, temporary recovery of cardiac function is mandatory. Enhancing cardiac function by a ␤-AR increase is potentially the treatment of choice. ␤-AR gene therapy may be advantageous in terms of improvement of quality of life in acute crisis of chronic heart failure, under enhanced sympathetic activation. Short-term adrenergic stimulation may be effective in weaning from large-dose catecholamine therapy, as well as the introduction of ␤-AR blockade therapy in severe cases. The therapy may also be applicable to temporal restoration of severe heart failure in patients to be treated by heart transplantation.
In conclusion, improved cardiac function was observed as a result of in vivo ␤ 2 -AR genetic transduction in an animal model with failing heart. This suggests new possibilities in molecular treatment of severe cardiac failure in which there are obstacles to the ␤-AR system, and which are resistant to conventional medical treatment. SalI 1.8 kb fragment from pTZ␤ 2 -AR kindly provided by Dr M Bouvier) [32] [33] [34] and E. coli ␤-gal gene, respectively. Both plasmids also possess the EBV oriP element, as well as the EBV nuclear antigen 1 (EBNA1) gene (Figure 1) . Animals Bio14.6 (cardiomyopathic hamsters) and F1b (normal golden hamsters) were purchased from Charles River Laboratories (Wilmington, MA, USA). As Bio14.6 grow older, they show manifestations of heart failure, ␤-ARs being down-regulated in the cardiomyocytes. 35 The FS of the Bio14.6 were 46.8 ± 4.17 and 13.46 ± 3.78 at 29 and 45 weeks of age, respectively, while that of the 45-week-old F1b was 40.78 ± 7.86. Therefore, we used 45-week-old Bio14.6 for the experiments.
Materials and methods

Gene transfer
The animals were anesthetized by intra-peritoneal injection with sodium thiobutabarbital (0.1 mg/kg). A DNA/20% sucrose solution (2 g/l) containing a small amount of carbon particles as a marker was percutaneously injected into the left ventricular wall, using a microsyringe with a 27G needle, under guidance of the echocardiography (Digital Sonolayer PowerVision SSA-380A equipped with a 7.5-MHz transducer; Toshiba, Tokyo, Japan). Approximately 40 l of the solution was injected at each of five locations.
Measurement of cardiac function
The animals were anesthetized by intra-peritoneal injection with sodium thiobutabarbital (0.1 mg/kg) and analyzed by blinded observers. The HR, FS, Dd and Ds parameters were individually measured by the echocardiographic device before or 5 min after percutaneous administration of 0.1 mg/kg of isoproterenol. The SV and CO were calculated according to following formula:
Statistical analysis
Differences in cardiac function data were assessed by use of a two way repeated-measures ANOVA. If a significant F ratio was obtained, further analysis was carried out with Fisher's PLSD post hoc test. Differences between groups were considered significant at P Ͻ 0.05.
X-gal staining
The F1b were killed on day 5 following pSES.␤ transduction. The hearts were excised, cut into slices and fixed with 2% paraformaldehyde for 4 h at 4°C. Following thorough rinsing with PBS, the slices were incubated in an X-gal staining solution (0.05% (v/v) 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (X-gal) (Nacalai Tesque, Kyoto, Japan), 1 mm MgCl 2 , 150 mm NaCl, 3 mm K 4 [Fe(CN) 6 ], 3 mm K 3 [Fe(CN) 6 ], 60 mm Na 2 HPO 4 , 40 mm NaH 2 PO 4 and 0.1% Triton X-100) for 3 h at 37°C.
␤2-AR immunohistochemistry
The Bio14.6 were killed on day 5 after pSES.␤ 2 -AR transduction. The hearts were excised, embedded in paraffin, and sliced to a thickness of 5 m. The slices were then incubated with an appropriate dilution of anti-human ␤ 2 -AR antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by rinsing with PBS and further incubation with peroxidase-labeled goat anti-rabbit immunoglobulin (EnVision; Dako, Carpinteria, CA, USA). The ␤ 2 -AR expression was visualized by treatment with DAB solution (Dako).
RT-PCR
The organs were removed from the dead animals and rinsed with PBS. RNA was extracted with ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol, and RT-PCR was performed as described elsewhere. 36 The combinations of SR␣-specific sense and ␤2-AR gene-specific antisense primers (5′-CCGCC TGTGGTGCCTCCTGA and 5′-TGCCCATGCCCACCA CCCAC, respectively) or ␤-actin gene-specific sense and antisense primers (5′-GTGCTATCCCTGTACGCCTC and 5′-AGTCCGCCTAGAAGCATTTG, respectively) were used ( Figure 1 ).
